starpharma

ASX Announcement

Appendix 4E: Preliminary Financial Report

under ASX Listing Rule 4.3A

Current reporting period: Year ended 30 June 2026
Prior corresponding period: Year ended 30 June 2025

Results for announcement to the market

	30 June 2026 $'000	30 June 2025 $'000	Movement %
Reported			
Revenue	**12,050**	4,912	Up 145%
Loss for the period attributable to members	**(7,465)**	(9,990)	Down 25%

Dividends

No dividends were paid or declared during the current period or during the previous corresponding period.

Explanation of Revenue

Revenue for the year was $12,050,000 (2025: $4,912,000) and included an $8,340,000 upfront payment under the Collaboration and License Agreement with Genentech. Revenue from customers also included product sales, royalties, other licence revenue and research revenue. Revenue increased by 145% compared with the prior year, primarily due to the Genentech upfront payment.

Explanation of Loss

The loss for the year was $7,465,000 (2025: $9,990,000), a decrease of 25% compared with the prior year. The improvement reflected increased revenue, partly offset by increased investment in research programs. Research and product development expenditure increased to $11,149,000 (2025: $8,355,000), net of the Australian Government's R&D tax incentive, and included the costs associated with advancing the internal DEP® HER2-Lutetium radiopharmaceutical program and next-generation DEP® candidates.

Net Tangible Assets

Net tangible assets per ordinary share as at 30 June 2026 were $0.03 (30 June 2025: $0.05).

Other

Additional Appendix 4E disclosure requirements, including further commentary on results are contained in the Annual Report for the year ended 30 June 2026. This report is based on the consolidated financial statements which have been audited by PricewaterhouseCoopers.